1-{[(2S,1R,4R,5R)-4-(6-chloropurin-9-yl)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl]methylthio}-2-fluorobenzene | 1072544-21-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-{[(2S,1R,4R,5R)-4-(6-chloropurin-9-yl)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl]methylthio}-2-fluorobenzene
• 英文别名: 1-{[(2S,1R,4R,5R)-4-(6-chloropurin-9-yl)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0)oct-2-yl]methylthio}-2-fluorobenzene；9-[(3aR,4R,6S,6aR)-6-[(2-fluorophenyl)sulfanylmethyl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-chloropurine
• CAS: 1072544-21-8
• 化学式: C₁₉H₁₈ClFN₄O₃S
• 分子量: 436.894
• InChiKey: FNZNHBANMXDENA-DQADVMEASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  96.6
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-{[(2S,1R,4R,5R)-4-(6-chloropurin-9-yl)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl]methylthio}-2-fluorobenzene 、 环戊胺 在 三乙胺 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 生成 (9-{(4S,1R,2R,5R)-4-[(2-fluorophenylthio)methyl]-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct-2-yl}purin-6-yl)cyclopentylamine
  参考文献：
  名称：

  Partial and full agonists of A1 adenosine receptors

  摘要：

  本发明涉及一种新型化合物，它们是A1腺苷受体的部分和完全激动剂，可用于治疗各种疾病状态，特别是心动过速和心房颤动、心绞痛和心肌梗死。

  公开号：

  US20030050275A1

文献信息

• Method for treating arrhythmias
  申请人：——

  公开号：US20030216349A1

  公开（公告）日：2003-11-20

  Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A 1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.

  提供了治疗心律失常的方法，以最小化不良副作用的方式，包括使用治疗有效的最小剂量A1腺苷受体激动剂与治疗有效的最小剂量β受体阻滞剂、钙通道阻滞剂或心脏苷。
• ABCA-1 ELEVATING COMPOUNDS AND METHODS
  申请人：Dhalla Arvinder

  公开号：US20090203689A1

  公开（公告）日：2009-08-13

  Disclosed are novel compounds of Formula I useful for treating various disease states, in particular, insulin resistance, diabetes, dyslipidemia, coronary artery disease, and inflammation. The compounds of the present invention elevate cellular expression of the ABCA-1 gene as well as increasing the level of ABCA-1 protein, which may result in an increase in HDL levels in the plasma of a mammal, in particular humans.

  本发明公开了一种公式I的新化合物，用于治疗各种疾病状态，特别是胰岛素抵抗、糖尿病、血脂异常、冠状动脉疾病和炎症。本发明的化合物提高了ABCA-1基因的细胞表达，同时增加了ABCA-1蛋白的水平，这可能导致哺乳动物，特别是人类血浆中HDL水平的增加。
• Method of treating arrhythmias
  申请人：Belardinelli Luiz

  公开号：US20060052333A1

  公开（公告）日：2006-03-09

  Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an Al adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.

  提供了一种治疗心律失常的方法，以最小化不良副作用，包括使用治疗有效的最小剂量的Al腺苷受体激动剂和治疗有效的最小剂量的β受体阻滞剂、钙通道阻滞剂或心脏苷。
• PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS
  申请人：Dhalla Arvinder

  公开号：US20090247557A1

  公开（公告）日：2009-10-01

  Disclosed are novel compounds a compound of Formula I that are partial and full A 1 adenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes, decreased insulin sensitivity, Polycystic Ovarian Syndrome, Stein-Leventhal syndrome, and obesity.

  本发明涉及一种新型化合物，其中化合物I的部分和完全A1腺苷受体激动剂，可用于治疗各种疾病状态，特别是血脂异常、糖尿病、胰岛素敏感性降低、多囊卵巢综合症、斯坦 - 莱文塔尔综合症和肥胖症。
• METHOD OF TREATING ARRHYTHMIAS
  申请人：Belardinelli Luiz

  公开号：US20090118221A1

  公开（公告）日：2009-05-07

  Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A 1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.

  提供了一种治疗心律失常的方法，以最小化不良副作用，包括给予治疗有效的极小剂量A1腺苷受体激动剂和治疗有效的极小剂量β受体阻滞剂、钙通道阻滞剂或心脏糖苷。